Patients undergoing haploidentical allo-HSCT will be prospectively enrolled exploring the NK cells phenotype and functional reconstitution.
Patients with hematological malignancies suitable for allo-HSCT but without HLA-identical related or unrelated donors were candidates for the HLA-haploidentical HSCT. Patients undergoing haploidentical allo-HSCT will be prospectively enrolled exploring the NK cells phenotype and functional reconstitution. Peripheral blood will be collected by day15, 30, 60, 90, 180, and 1 year post transplantation.
Study Type
OBSERVATIONAL
Enrollment
200
Peking University Institute of Hematology
Beijing, Beijing Municipality, China
RECRUITINGImmune Reconstitution differences between two group
Time frame: 1 year
Cumulative incidence of Infection differences between two group
Time frame: 1 year
Cumulative incidence of acute GVHD differences between two group
Time frame: 100 day
Cumulative incidence of chronic GVHD differences between two group
Time frame: 1 year
Cumulative incidence of TRM differences between two group
Time frame: 1 year
Cumulative incidence of relapse differences between two group
Time frame: 1 year
DFS differences between two group
Time frame: 1 year
OS differences between two group
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.